Results 181 to 190 of about 24,787 (310)

The SWITCH algorithm: An expert consensus on treat‐to‐target criteria for chronic prurigo

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The SWITCH project assessed patients' most distressing symptoms and therapy goals, followed by an expert‐based consensus procedure to define T2T criteria for patients with chronic prurigo (CPG)/prurigo nodularis. Based on these validated criteria, a 4‐step SWITCH algorithm was established to enhance CPG therapy outcomes and reduce patient burden ...
Lea S. Stahl   +16 more
wiley   +1 more source

Real-World Response to Dupilumab as Add-on Therapy in Adults and Adolescents with Type 2 Severe Asthma: A Spanish Cohort Study. [PDF]

open access: yesJ Asthma Allergy
Montoro Ferrer A   +10 more
europepmc   +1 more source

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat   +22 more
wiley   +1 more source

Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis

open access: diamond, 2020
И. С. Крысанов   +3 more
openalex   +2 more sources

Dupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nina Matthes   +6 more
wiley   +1 more source

Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The results of this French Early Access Program were consistent with those reported in dupilumab randomized clinical trials in children aged 6 months–5 years with moderate‐to‐severe AD. This research offers insights into the practical use of dupilumab in routine clinical practice.
Audrey Lasek   +9 more
wiley   +1 more source

Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis [PDF]

open access: hybrid
Claus Bachert   +19 more
openalex   +1 more source

Perioperative adjuvant therapy with short course of dupilumab with ESS for recurrent CRSwNP [PDF]

open access: hybrid
Audrey Pelletier   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy